Health Economics›Mantle cell lymphoma›Relapsed or refractory randomized data

Relapsed or refractory randomized data

Mantle cell lymphoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 11 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~22.1 mo	~30.3 mo	~25	~R 2 003 321 PFS proxy · indirect	2
Acalabrutinib monotherapy Variant #01	—	R 79 217	28d	~38.4 mo	—	~42	~R 3 327 127 PFS proxy · indirect	4
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	—	—	4
Cladribine monotherapy Variant #01	—	R 59 905	5d	—	—	—	—	—
R-FCM Variant #04	—	R 46 093	42d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~51.3 mo	—	~56	~R 2 285 190 PFS proxy · indirect	4
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 26 364	—	~5.2 mo	—	—	—	1
R-HAD Variant #01	—	R 15 072	21d	—	—	—	—	—
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~5.2 mo	—	~3	~R 42 639 PFS proxy · indirect	1
Fludarabine monotherapy Variant #01	—	R 11 691	28d	~5.2 mo	—	~6	~R 70 145 PFS proxy · indirect	1
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~8.7 mo	—	~3	~R 19 084 PFS proxy · indirect	2
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 3 662	28d	~5.2 mo	—	~6	~R 21 970 PFS proxy · indirect	1
BCHOP Variant #01	—	R 3 506	21d	—	~35.6 mo	—	—	1
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	~5.2 mo	—	~12	~R 30 274 PFS proxy · indirect	1
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~5.2 mo	—	~1	~R 52 PFS proxy · indirect	3
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~23.5 mo	~6	~R 1 PFS proxy · indirect	2

16 of 16 regimens shown